Chitosan and Hyaluronic Acid Nanoparticles as Vehicles of Epoetin Beta for Subconjunctival Ocular Delivery.
chitosan
epoetin beta
erythropoietin
hyaluronic acid
mucoadhesion
nanoparticles
ocular delivery
Journal
Marine drugs
ISSN: 1660-3397
Titre abrégé: Mar Drugs
Pays: Switzerland
ID NLM: 101213729
Informations de publication
Date de publication:
18 Feb 2022
18 Feb 2022
Historique:
received:
31
12
2021
revised:
31
01
2022
accepted:
11
02
2022
entrez:
24
2
2022
pubmed:
25
2
2022
medline:
17
3
2022
Statut:
epublish
Résumé
Neuroprotection in glaucoma using epoetin beta (EPOβ) has yielded promising results. Our team has developed chitosan-hyaluronic acid nanoparticles (CS/HA) designed to carry EPOβ into the ocular globe, improving the drug's mucoadhesion and retention time on the ocular surface to increase its bioavailability. In the present in vivo study, we explored the possibility of delivering EPOβ to the eye through subconjunctival administration of chitosan-hyaluronic acid-EPOβ (CS/HA-EPOβ) nanoparticles. Healthy Wistar Hannover rats (
Identifiants
pubmed: 35200680
pii: md20020151
doi: 10.3390/md20020151
pmc: PMC8878220
pii:
doi:
Substances chimiques
Drug Carriers
0
Recombinant Proteins
0
epoetin beta
0
Erythropoietin
11096-26-7
Hyaluronic Acid
9004-61-9
Chitosan
9012-76-4
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Fundação para a Ciência e a Tecnologia (FCT), Portugal
ID : UID/DTP/04138/2019 and UIDB/04138/2020 to iMed.ULisboa, and by national funds through FCT, I.P., Project UIDB/00276/2020.); principal investigator grants CEECIND/03143/2017 (L. M.G) & SFRH/BD/130476/2017 (B.S.)
Références
Invest Ophthalmol Vis Sci. 2005 Dec;46(12):4617-21
pubmed: 16303957
Int J Pharm. 2020 Feb 25;576:119020
pubmed: 31935477
J Exp Biol. 2004 Aug;207(Pt 18):3233-42
pubmed: 15299044
Adv Drug Deliv Rev. 2006 Nov 15;58(11):1164-81
pubmed: 17069929
Biomed Hub. 2018 Jul 13;3(2):1-11
pubmed: 31988957
Optometry. 2011 Jan;82(1):38-43
pubmed: 21146792
Adv Drug Deliv Rev. 2001 Nov 5;52(2):117-26
pubmed: 11718935
Pharmaceutics. 2018 Aug 01;10(3):
pubmed: 30071584
Acta Ophthalmol. 2011 May;89(3):e269-73
pubmed: 20946333
Doc Ophthalmol. 2005 Jan;110(1):57-66
pubmed: 16249957
Graefes Arch Clin Exp Ophthalmol. 2013 Aug;251(8):2051-6
pubmed: 23702929
Ophthalmic Res. 2016 Jul;56(2):104-10
pubmed: 27077922
ISRN Ophthalmol. 2012 May 22;2012:346297
pubmed: 24555124
Vision Res. 2001 Aug;41(17):2173-85
pubmed: 11448710
Prog Retin Eye Res. 2008 Jan;27(1):1-44
pubmed: 18042420
Carbohydr Polym. 2021 Sep 1;267:118217
pubmed: 34119171
Eur J Pharm Biopharm. 2005 Jul;60(2):227-40
pubmed: 15939235
J Physiol. 1973 Feb;228(3):781-97
pubmed: 4702156
J Drug Target. 2010 May;18(4):292-302
pubmed: 19943753
Eur J Pharm Biopharm. 2012 Aug;81(3):463-9
pubmed: 22561955
Surv Ophthalmol. 2022 Mar-Apr;67(2):427-439
pubmed: 34157346
Diabetes Care. 2008 Jun;31(6):1189-94
pubmed: 18332162
Mol Med. 2015 Dec;21(1):803-815
pubmed: 26349059
Biomed Pharmacother. 2018 Nov;107:1564-1582
pubmed: 30257375
Int J Pharm. 2001 Aug 14;224(1-2):159-68
pubmed: 11472825
Diabetes Care. 2006 Sep;29(9):2028-33
pubmed: 16936148
Drug Deliv. 2016;23(3):710-26
pubmed: 24892625
Prog Retin Eye Res. 2012 Jan;31(1):1-27
pubmed: 21946033
J Curr Ophthalmol. 2016 Mar 30;28(1):5-11
pubmed: 27239595
Int J Pharm. 2021 Sep 5;606:120873
pubmed: 34246741
Pharmaceutics. 2020 Mar 16;12(3):
pubmed: 32188045
Drug Deliv Transl Res. 2017 Oct;7(5):625-631
pubmed: 28639139
Ophthalmic Res. 2015;53(2):74-81
pubmed: 25592771
Aging Male. 2018 Jun;21(2):145-148
pubmed: 28696817